A Search Service for Abbreviation / Long Form

â–  Abbreviation / Long Form : IL-5 / anti-interleukin-5

[Related PubMed/MEDLINE]
Total Number of Papers: 20
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IL-5  (>> Co-occurring Abbreviation)
Long Form:   anti-interleukin-5
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study. AERD, GETE, OCS, SEA
2020 Exacerbations of Severe Asthma While on Anti-IL-5 Biologics. ---
2020 In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility. EOS, FEV1
2020 Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. ACT, OCS, SPT
2020 Role of eosinophilic chronic rhinosinusitis inswitching to benralizumab treatment in mepolizumab responders
. ECRS
2020 The use of biologic therapies for the management of pediatric asthma. ---
2018 Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. EGPA, s.c
2018 New biologics for allergic diseases. IgE
2017 Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. IL-5Ra
10  2017 Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. EMA, FDA
11  2015 Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. DREAM, RCT
12  2012 Targeting of eosinophils in asthma. ---
13  2010 Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. FIP1L1-PDGFRA, HES
14  1997 Effects of inhibitors of inflammatory mediators and cytokines on eosinophil and neutrophil accumulation induced by Mycobacterium bovis bacillus Calmette-Guerin in mouse pleurisy. BCG, mAb
15  1995 Lung eosinophilia is dependent on IL-5 and the adhesion molecules CD18 and VLA-4, in a guinea-pig model. BAL, EPO, mAb
16  1994 Regulatory effect of anti-interleukin-5 monoclonal antibody on intestinal worm burden in a primary infection with strongyloides venezuelensis in mice. ---
17  1994 The effect of anti-tumor necrosis factor (TNF)-alpha monoclonal antibody on allergic cutaneous late phase reaction in mice. DNFB, DNP, TNF
18  1993 Aspergillus fumigatus antigen induced eosinophilia in mice is abrogated by anti-IL-5 antibody. ABPA, BM, EPO, PB
19  1992 Interleukin-5 in eosinophilic gastroenteritis. G-CSF
20  1990 Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. EMS, GM-CSF